Condensed Consolidated Statements of Operations (USD $)	3 Months Ended		9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2014	Sep. 30, 2013
Revenue
Product revenue	$ 12,595,044	$ 2,535,153	$ 28,336,212	$ 12,786,935
Service revenue	6,914,933	1,629,855	13,395,506	4,552,528
Research and development contract revenue	371,117	461,808	1,045,059	1,229,734
Total revenue	19,881,094	4,626,816	42,776,777	18,569,197
Cost of product revenue	11,058,189	3,909,606	24,950,538	14,339,351
Cost of service revenue	9,217,120	3,902,412	19,143,276	10,444,167
Cost of research and development contract revenue	699,490	730,486	1,887,516	1,883,361
Research and development expense	1,643,526	768,965	4,295,153	2,343,030
Selling, general and administrative expenses	4,950,594	2,753,030	13,033,958	8,849,730
Legal reserve	2,400,000		2,400,000
Amortization of intangible assets	608,444	562,896	1,782,832	1,704,917
Operating loss	(10,696,269)	(8,000,579)	(24,716,496)	(20,995,359)
Interest and other income	628,339	26,028	722,118	83,109
Gain on bargain purchase			1,014,256
Change in fair value of common stock warrant liability	485,471	(8,206,429)	(58,370,871)	(16,171,061)
Interest and other expense	(93,255)	(124,651)	(304,863)	(354,180)
Gain on sale of equity interest in joint venture				3,234,717
Loss before income taxes	(9,675,714)	(16,305,631)	(81,655,856)	(34,202,774)
Income tax benefit	324,680	410,259	324,680	410,259
Net loss attributable to the Company	(9,351,034)	(15,895,372)	(81,331,176)	(33,792,515)
Preferred stock dividends declared	(26,030)	(51,908)	(129,848)	(69,211)
Net loss attributable to common shareholders	$ (9,377,064)	$ (15,947,280)	$ (81,461,024)	$ (33,861,726)
Loss per share:
Basic and diluted (in dollars per share)	$ (0.06)	$ (0.19)	$ (0.53)	$ (0.50)
Weighted average number of common shares outstanding (in shares)	169,557,223	84,150,851	154,539,225	67,194,806